Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261050
3.
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Future Oncol
; 17(17): 2225-2241, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724868
4.
Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies.
EJNMMI Phys
; 11(1): 18, 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372952
5.
Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging.
PET Clin
; 19(2): 261-279, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38199918
6.
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
Eur Urol
; 85(3): 217-226, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37891072
7.
Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol
; 15: 17588359231179309, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37323184
8.
Comparison of dual-energy CT with positron emission tomography for lung perfusion imaging in patients with non-small cell lung cancer.
Phys Med Biol
; 68(3)2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623318
9.
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.
Ther Adv Med Oncol
; 15: 17588359231177018, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37323189
10.
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.
Eur Urol Oncol
; 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061976
11.
AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).
Front Med (Lausanne)
; 9: 1059122, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36465905
12.
Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome.
Cerebellum
; 9(3): 443-53, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20559786
13.
Is 161Tb Really Happening?
J Nucl Med
; 65(5): 686-687, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38604760
14.
The evolving definition of bulky disease for lymphoma.
Leuk Lymphoma
; 61(7): 1525-1528, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32684049
15.
The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study.
Am J Alzheimers Dis Other Demen
; 25(4): 324-32, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20539026